Insider Sale: ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS)’s SVP – Antisense … – OctaFinance.com

STORMInsider Sale: ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS)’s SVP – Antisense …OctaFinance.comThe SVP – Antisense Research of ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS) 62.77 +0.73 1.18% and corporation’s insider Frank Bennett unloaded 5,000 shares of the -listed Isis Pharmaceuticals Inc based on the stock price per share of $64.0 of a share.Joseph Klein Unloaded $441234 Worth of ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS …FinancialMagazin.comInsider Selling: C Frank Bennett Sells 5000 Shares of ISIS Pharmaceuticals …Voice ChronicleISIS Pharmaceuticals Director Joseph Klein III Sells 6875 Shares (ISIS)Dakota Financial NewsMidSouth Newz -STORMall 13 news articles »

Read More

ISIS Pharmaceuticals Director Joseph Klein III Sells 6875 Shares (ISIS) – Dakota Financial News

STORMISIS Pharmaceuticals Director Joseph Klein III Sells 6875 Shares (ISIS)Dakota Financial NewsThe Firm is focused to discover and develop antisense drugs. The antisense drugs are utilized to deal with a range of diseases, including cardiovascular, infrequent, serious and metabolic diseases. ISIS-APOCIII is a drug demonstrated to to treat …Insider Selling: C Frank Bennett Sells 5000 Shares of ISIS Pharmaceuticals …Voice ChronicleNeedham & Company LLC Lowers ISIS Pharmaceuticals Price Target to $88.00 (ISIS)STORMall 9 news articles »

Read More

Idera begins enrollment in IMO-8400 Phase 2 clinical trial for treatment of dermatomyositis

Idera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing Toll-like receptor (TLR) and RNA therapeutics for patients with cancer and rare diseases, today announced that the company has commenced enrollment in a Phase 2 clinical trial of IMO-8400, an investigational TLR 7, 8 and 9 antagonist, in patients with dermatomyositis. Dermatomyositis is a rare and debilitating inflammatory muscle and skin disease associated with significant morbidity, decreased quality of life and an increased risk of premature death.

Read More

ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS) SVP – Antisense Research Frank … – FinancialMagazin.com

The San Diego Union-TribuneISIS Pharmaceuticals, Inc. (NASDAQ:ISIS) SVP – Antisense Research Frank …FinancialMagazin.comIn consideration of sell Frank Bennett made he is in the insider trading spotlight today. The SVP – Antisense Research of Isis Pharmaceuticals Inc and an insider, made a sale of 5,000 shares worth $280,000 USD. The average price was $56.0 per share.Isis Pharma jumps 12 percentThe San Diego Union-TribuneWhy Isis Pharmaceuticals Is More Potent TodayMotley FoolISIS Pharmaceuticals Price Target Raised to $65.00 at Barclays (ISIS)Dakota Financial NewsZacks.com -PR Newswire (press release) -Voice Chronicleall 42 news articles »

Read More

Isis Pharmaceuticals Earns $2.8M for Advancing ISIS-DMPK-2.5 Rx in Patients … – PR Newswire (press release)

Phys.OrgIsis Pharmaceuticals Earns $2.8M for Advancing ISIS-DMPK-2.5 Rx in Patients …PR Newswire (press release)Isis is primarily responsible for drug discovery and early development of antisense therapies. Biogen has the option to license each antisense program at a particular stage in development. Current development-stage programs include antisense drugs to …Company Update (NASDAQ:ISIS): ISIS Pharmaceuticals, Inc. Earns $2.8M for …Smarter AnalystCurrent Trade Stocks Recap: Southwest Airlines Co (NYSE:LUV), ISIS …wsnewspublishersall 11 news articles »

Read More

Isis Pharma jumps 12 percent – The San Diego Union-Tribune

The San Diego Union-TribuneIsis Pharma jumps 12 percentThe San Diego Union-TribuneThe company says it is progressively refining antisense to make it more potent, and this will be reflected in newer generations of drugs. Volansorsen and ISIS-APO(a)Rx are considered advanced second-generation antisense drugs. None of the antisense …Why Isis Pharmaceuticals Is More Potent TodayMotley FoolIsis Pharmaceuticals (ISIS) Q3 Loss Narrower than ExpectedZacks.comIsis Reports Financial Results and Highlights for Third Quarter 2015PR Newswire (press release)Street Report -Nasdaqall 42 news articles »

Read More

Global Antisense and RNAi Therapeutics Market 2015 Clinical Trails, Research … – Medgadget.com (blog)

Medgadget.com (blog)Global Antisense and RNAi Therapeutics Market 2015 Clinical Trails, Research …Medgadget.com (blog)Global Antisense and RNAi Therapeutics Market 2015-2019Antisense and RNAi therapeutics are new innovative therapeutics options that are used in the treatment of serious chronic and rare diseases. RNAi is a RNA-based gene silencing process in which …

Read More

Isis Pharmaceuticals Inc (NASDAQ:ISIS) Institutional Investors Sentiment Index … – FinancialMagazin.com

StreetWise ReportIsis Pharmaceuticals Inc (NASDAQ:ISIS) Institutional Investors Sentiment Index …FinancialMagazin.comThe Firm is focused to discover and develop antisense drugs. It has 275.02 P/E ratio. The antisense drugs are used to treat a range of diseases, including cardiovascular, metabolic, severe and rare diseases, including neurological disorders and cancer.Isis Pharma begins phase 2 study of ISIS-FXI Rx in patients with ESRD on …pharmabiz.comIsis starts phase 2 study of ISIS-FXIRx drugPharmaceutical Business Reviewall 5 news articles »

Read More

Emerging Biotechnologies -Antisense RNAi Therapeutics Industry 2015 Global … – Medgadget.com (blog)

Medgadget.com (blog)Emerging Biotechnologies -Antisense RNAi Therapeutics Industry 2015 Global …Medgadget.com (blog)2. Global Emerging Biotechnologies -Antisense RNAi Therapeutics Industry 2015 Review, Research, Size, Share, Industry Analysis, Trends and Forecast 2025 3. This report provides top line data relating to the clinical trials 4. Report includes an …and more »

Read More

Ultragenyx, Arcturus sign agreement to develop mRNA therapeutics to certain rare diseases

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, and Arcturus Therapeutics, Inc., a leading RNA medicines company, today announced that they have entered into a research collaboration and license agreement to discover and develop messenger RNA (mRNA) therapeutics to certain rare disease targets using Arcturus’ UNA Oligomer chemistry and LUNAR nanoparticle delivery platform.

Read More

Ultragenyx, Arcturus Launch Up-to-$1.56B+ Rare Disease Collaboration – Genetic Engineering & Biotechnology News

News-Medical.netUltragenyx, Arcturus Launch Up-to-$1.56B+ Rare Disease CollaborationGenetic Engineering & Biotechnology NewsArcturus’ platform is designed to be applied toward all RNA therapeutics—including small interfering RNA, messenger RNA, antisense RNA, microRNA, and gene-editing therapeutics. The company’s UNA technology can target any gene in the human …Ultragenyx Pharmaceutical and Arcturus Therapeutics Announce a Research …CNNMoneyall 11 news articles »

Read More

Four microRNAs appear to play critical roles in controlling cholesterol, triglyceride metabolism

Four tiny segments of RNA appear to play critical roles in controlling cholesterol and triglyceride metabolism. In their report receiving advance online publication in Nature Medicine, a Massachusetts General Hospital-based research team describes finding how these microRNAs could reduce the expression of proteins playing key roles in the generation of beneficial HDL cholesterol, the disposal of artery-clogging LDL cholesterol, control of triglyceride levels and other risk factors of cardiovascular disease.

Read More

Global merging Biotechnologies Antisense RNAi Market 2015 ,Size, Share, Trail … – Medgadget.com (blog)

Medgadget.com (blog)Global merging Biotechnologies Antisense RNAi Market 2015 ,Size, Share, Trail …Medgadget.com (blog)Emerging-Biotechnologies2 Emerging Biotechnologies – Antisense RNAi Therapeutics Market Analysis report is an essential source of information and analysis on the RNA interference (RNAi) therapy field. Using detailed company data, deal analysis, …

Read More

ISIS Pharmaceuticals Given Average Recommendation of “Hold” by Analysts … – Dakota Financial News

ISIS Pharmaceuticals Given Average Recommendation of “Hold” by Analysts …Dakota Financial NewsThe Firm is focused to find and develop antisense drugs. The antisense drugs are accustomed to take care of a range of diseases, including cardiovascular, metabolic, acute and rare diseases. ISIS APOCIII is a drug demonstrated to to treat patients with …and more »

Read More

PharmaSphere: Emerging Biotechnologies – Antisense RNAi Therapeutics Market … – GlobeNewswire (press release)

PharmaSphere: Emerging Biotechnologies – Antisense RNAi Therapeutics Market …GlobeNewswire (press release)Albany – NY, Oct. 21, 2015 (GLOBE NEWSWIRE) — “PharmaSphere: Emerging Biotechnologies Antisense RNAi Therapeutics Market Analysis” report is an essential source of information and analysis on the RNA interference (RNAi) therapy field.and more »

Read More

X-Chromosome Silencing Depends on Antisense RNA – Genetic Engineering & Biotechnology News

Genetic Engineering & Biotechnology NewsX-Chromosome Silencing Depends on Antisense RNAGenetic Engineering & Biotechnology NewsThink of the silencing of the X chromosome as a construction project. Then, imagine you hear the beeping of heavy machinery operating in reverse. That’s the sound of the Xist gene being transcribed in the backwards, or antisense, direction. The Xist …Female cells use RNA to turn off X chromosomeFuturity: Research NewsX-citing X chromosome discovery could aid research on many sex-linked disordersPhys.Orgall 9 news articles »

Read More

First patients receive doses of antisense drug for Huntington’s disease – News-Medical.net

BBC NewsFirst patients receive doses of antisense drug for Huntington’s diseaseNews-Medical.net’Gene silencing’ drugs, also known as ‘antisense’ drugs, are designed to reduce production of a chosen protein by attaching to the mRNA ‘message molecule’ that’s made whenever a gene is activated. ISIS-HTTRx targets the huntingtin message molecule, …Liftoff: First humans treated with gene silencing drugs for HD!HDBuzzFirst human trial for innovative new drug in development to treat Huntington’s …HealthCanal.com (press release) (blog)all 8 news articles »

Read More